1-5 of 5
Emily Hsu, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Jan A. Burger, MD PhD, Tadeusz Robak, MDPhD, Fatih Demirkan, MD, Osnat Bairey, MD, Carol Moreno, MD PhD, David Simpson, MBChB, FRACP, FRCPA, Talha Munir, MBBS, Don A. Stevens, MD, Sandra Dai, PhD MS, Leo W. K. Cheung, PhD, Kevin Kwei, PhD, Indu Lal, MD, Emily Hsu, PhD, Thomas J. Kipps, MD PhD, Alessandra Tedeschi, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-134437
Published: 2020
Journal Articles

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Carol Moreno, MD PhD, Richard Greil, MD, Fatih Demirkan, MD, Alessandra Tedeschi, MD, Bertrand Anz, MD, Loree Larratt, MD, Martin Simkovic, MD PhD, Olga Samoilova, MD, Jan Novak, MD PhD, Dina Ben-Yehuda, MD, Vladimir Strugov, MD, Devinder Gill, MD MRCP, FRCPath, John G. Gribben, Emily Hsu, PhD, Cathy Zhou, MS, Fong Clow, ScD, Danelle F. James, MD MAS, Lori Styles, MD, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 691.
https://doi.org/10.1182/blood-2018-99-111370
Published: 2018
Journal Articles

Changes in Clinical Stage Identify Different Response Categories Among Patients in Iwcll PR: Analysis of CLL Patients on the Resonate Study

Carol Moreno, MD, Julio Delgado, MD, John C. Byrd, MD, William L. Zvagelsky, Samuel Suzuki, MS, MBA, Emily Hsu, PhD, Danelle F. James, MD MAS, Emili Montserrat, MD
Journal: Blood
Blood (2016) 128 (22): 4384.
https://doi.org/10.1182/blood.V128.22.4384.4384
Published: 2016
Journal Articles

Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jacqueline C. Barrientos, MD, Susan O'Brien, Jennifer R. Brown, MD PhD, Neil E. Kay, MD, Nishitha M. Reddy, MBBS, Steven Coutre, MD, Constantine Tam, MD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Ulrich Jaeger, MD, Steve Devereux, MD, Christopher Pocock, MD PhD, Tadeusz Robak, MD, Stephen J. Schuster, MD, Anna Schuh, MDPhD, Devinder Gill, MD, Adrian Bloor, PhD FRCPath, Claire Dearden, MD, Carol Moreno, MD, Gavin Cull, MBBS, DM, FRACP, FRCPA, Michael Hamblin, Jeffrey A. Jones, MD, Tanja Kierschniak, Karl Eckert, BA, Samuel Suzuki, MS, MBA, Emily Hsu, PhD, Danelle F. James, MD MAS, John C. Byrd, MD, Peter Hillmen, MB, ChB, PhD
Journal: Blood
Blood (2014) 124 (21): 4696.
https://doi.org/10.1182/blood.V124.21.4696.4696
Published: 2014
Journal Articles

Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report

Marco Montillo, MD, Susan O'Brien, MD, Alessandra Tedeschi, MD, Peter Hillmen, MB, ChB, PhD, Claire Dearden, MD, Devinder Gill, MD, Jennifer R. Brown, MD PhD, Jaqueline C. Barrientos, MD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Richard R. Furman, MD, Florence Cymbalista, MD, Clara Plascencia, Stephen Chang, PhD, Emily Hsu, PhD, Danelle F. James, MD MAS, John C. Byrd, MD
Journal: Blood
Blood (2014) 124 (21): 5654.
https://doi.org/10.1182/blood.V124.21.5654.5654
Published: 2014